Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial

Arthritis and Rheumatism
Josef S SmolenActive-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) S

Abstract

To identify disease characteristics leading to progression of joint damage in patients with early rheumatoid arthritis (RA) treated with methotrexate (MTX) versus those treated with infliximab plus MTX. Patients who had not previously been treated with MTX with active RA were randomly assigned to receive escalating doses of MTX up to 20 mg/week plus placebo or infliximab at weeks 0, 2, and 6, and every 8 weeks thereafter through week 46. Radiographic joint damage was assessed using the modified Sharp/van der Heijde score (SHS). The relationship between disease activity measures at baseline and week 14, as well as those averaged over time, were examined in relation to the change in SHS from baseline through week 54. C-reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), and swollen joint count were associated with greater joint damage progression in the MTX-only group, while none of these parameters was associated with progression in the infliximab plus MTX group. Mean changes in SHS among patients in the highest CRP (> or = 3 mg/dl) and ESR (> or = 52 mm/hour) tertiles in the MTX-only group were 5.62 and 5.89, respectively, compared with 0.73 and 1.12 in the infliximab plus MTX group (P < 0.001). Patients with g...Continue Reading

References

Feb 1, 1984·Annals of the Rheumatic Diseases·D L ScottP A Bacon
Feb 1, 1980·Arthritis and Rheumatism·J F FriesH R Holman
Jan 1, 1996·Annual Review of Immunology·M FeldmannR N Maini
Dec 16, 1998·British Journal of Rheumatology·A A StengerM H van Rijswijk
Nov 30, 2000·The New England Journal of Medicine·J M BathonB K Finck
Sep 15, 2001·Annals of the Rheumatic Diseases·L M JansenB A Dijkmans
May 16, 2003·Nature·Gary S Firestein
May 31, 2003·Nature Reviews. Drug Discovery·Josef S Smolen, Günter Steiner
Oct 9, 2003·Annals of the Rheumatic Diseases·M E Weinblatt
Dec 16, 2003·Arthritis and Rheumatism·Kurt RedlichJosef S Smolen
Mar 6, 2004·Lancet·Lars KlareskogUNKNOWN TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators
Nov 6, 2004·Arthritis and Rheumatism·E William St ClairUNKNOWN Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Grou

❮ Previous
Next ❯

Citations

Jan 5, 2011·Clinical Rheumatology·Philip G Conaghan
Dec 4, 2012·Dermatology and Therapy·Bruce E StroberMelodie Young
Sep 2, 2009·Nature Reviews. Drug Discovery·Jeffrey G Stoll, Uma Yasothan
Jul 29, 2009·Nature Reviews. Rheumatology·Alla SkapenkoHendrik Schulze-Koops
Oct 3, 2009·Nature Reviews. Rheumatology·Yongwon ChoiMichael J Townsend
Oct 3, 2009·Nature Reviews. Rheumatology·Peter C Taylor, Marc Feldmann
Feb 26, 2010·Rheumatology·Masashizu NagaharaTakanobu Otsuka
Oct 21, 2010·Rheumatology·Antonios Stavropoulos-KalinoglouGeorge D Kitas
May 31, 2011·Rheumatology·M Gema Bonilla-HernánEmilio Martin-Mola
Feb 7, 2007·Current Opinion in Rheumatology·Jenny E Heller, Nancy A Shadick
Apr 7, 2007·Current Opinion in Rheumatology·Gust VerbruggenDirk Elewaut
Apr 5, 2008·Current Opinion in Rheumatology·Hernan Castro-Rueda, Arthur Kavanaugh
Mar 24, 2011·Current Opinion in Rheumatology·Josef S Smolen, Daniel Aletaha
Mar 6, 2012·Current Opinion in Rheumatology·Yoshiya Tanaka
Jan 24, 2009·Medical Care·Florina ConstantinescuLiana Fraenkel
Oct 22, 2008·Annals of the Rheumatic Diseases·M WongB Kirkham
Mar 11, 2010·Annals of the Rheumatic Diseases·Josef S SmolenUNKNOWN T2T Expert Committee
Apr 4, 2007·Postgraduate Medical Journal·Annabel KuekAndrew J K Ostör
Aug 2, 2011·The Journal of Clinical Investigation·Jason J SongWilliam H Robinson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved